Compare ARK Genomic Revolution ETF (ARKG) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Veritone Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.62, while Veritone Inc trades at $1.55 (market cap $138.04M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | VERI | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $8.39 |
52-Week Low | $24.02 | $1.00 |
Market Cap | — | $138.04M |
Enterprise Value | — | $170.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
Veritone (VERI) trades at $1.52, up 5.56% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, though revenue remains around $90-92 million. Recent news highlights partnerships in AI and public safety, but the stock faces headwinds from a securities class action lawsuit with a July 20, 2026 deadline.
The outlook is mixed: analyst consensus is evenly split between Buy and Hold ratings, but persistent losses and legal risks overshadow growth initiatives. Investment opportunity hinges on Veritone's ability to monetize its AI solutions and achieve profitability, while key risks include ongoing litigation and competitive pressures in the enterprise AI space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
